- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04233073
Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery (Annexa-S)
February 24, 2023 updated by: Alexion
Prospective, Open-Label Clinical Study of Andexanet Alfa in Patients Receiving FXa (Activated Factor X) Inhibitor Who Require Urgent Surgery
Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.
Study Overview
Detailed Description
This is a multicenter, prospective, open-label study to determine the efficacy and safety of andexanet in patients who require urgent surgery who have received 1 of the following FXa inhibitors: apixaban, rivaroxaban, edoxaban, or enoxaparin.
The start of surgery must be within 15 hours following the last dose of FXa inhibitor.
The primary efficacy outcome will be adjudicated by an independent Endpoint Adjudication Committee.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Graz, Austria, 8036
- Clinical Trial Site
-
Innsbruck, Austria, 6020
- Clinical Trial Site
-
Klagenfurt am Wörthersee, Austria, 9020
- Clinical Trial Site
-
Wien, Austria, 1090
- Clinical Trial Site
-
-
-
-
-
Clermont-Ferrand, France, 63003
- Clinical Trial Site
-
Dijon, France, 21070
- Clinical Trial Site
-
Lille, France, 59037
- Clinical Trial Site
-
Nantes, France, 44093
- Clinical Trial Site
-
Paris, France, 75012
- Clinical Trial Site
-
Paris, France, 75679
- Clinical Trial Site
-
-
-
-
-
Aachen, Germany, 52074
- Clinical Trial Site
-
Bonn, Germany, 53127
- Clinical Trial Site
-
Dortmund, Germany, 44137
- Clinical Trial Site
-
Freiburg, Germany, 79106
- Clinical Trial Site
-
Gießen, Germany, 35392
- Clinical Trial Site
-
Heidelberg, Germany, 69120
- Clinical Trial Site
-
Konstanz, Germany, 78464
- Clinical Trial Site
-
Köln, Germany, 51109
- Clinical Trial Site
-
Mainz, Germany, 55131
- Clinical Trial Site
-
Murnau Am Staffelsee, Germany, 82418
- Clinical Trial Site
-
Würzburg, Germany, 97080
- Clinical Trial Site
-
-
-
-
-
Ashkelon, Israel, 7830604
- Clinical Trial Site
-
Haifa, Israel, 3109601
- Clinical Trial Site
-
Jerusalem, Israel, 9103102
- Clinical Trial Site
-
Jerusalem, Israel, 92100
- Clinical Trial Site
-
Petah Tikva, Israel, 4941492
- Clinical Trial Site
-
-
-
-
-
Kamakura, Japan, 247-8533
- Clinical Trial Site
-
Kasuga, Japan, 816-0864
- Clinical Trial Site
-
Kawasaki, Japan, 216-8511
- Clinical Trial Site
-
Kumamoto, Japan, 860-0008
- Clinical Trial Site
-
Kumamoto, Japan, 861-8520
- Clinical Trial Site
-
Kurume, Japan, 830-8543
- Clinical Trial Site
-
Nagoya, Japan, 466-8650
- Clinical Trial Site
-
Sakai, Japan, 593-8304
- Clinical Trial Site
-
Sendai, Japan, 980-8574
- Clinical Trial Site
-
Tokyo, Japan, 113-8602
- Clinical Trial Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85006
- Clinical Trial Site
-
Tucson, Arizona, United States, 85724
- Clinical Trial Site
-
-
California
-
Long Beach, California, United States, 90806
- Clinical Trial Site
-
Moreno Valley, California, United States, 92555
- Clinical Trial Site
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- Clinical Trial Site
-
-
Florida
-
Sarasota, Florida, United States, 34239
- Clinical Trial Site
-
Tampa, Florida, United States, 33606
- Clinical Trial Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Clinical Trial Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Clinical Trial Site
-
Boston, Massachusetts, United States, 02111
- Clinical Trial Site
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Clinical Trial Site
-
-
New York
-
Staten Island, New York, United States, 10305
- Clinical Trial Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Clinical Trial Site
-
Durham, North Carolina, United States, 27710
- Clinical Trial Site
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Clinical Trial Site
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74104
- Clinical Trial Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Clinical Trial Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Clinical Trial Site
-
Pittsburgh, Pennsylvania, United States, 15212
- Clinical Trial Site
-
Pittsburgh, Pennsylvania, United States, 15213
- Clinical Trial Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 84 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
All of the following criteria must be met for the patient to be eligible:
- Either the patient or their medical proxy (or legal designee) has given written informed consent.
- Age ≥ 18 and < 85 years old.
- Requires urgent surgical intervention that must occur within 12 hours of consent, for which reversal of anti-fXa activity is judged necessary.
- Treatment with an oral FXa inhibitor (apixaban [last dose 2.5 mg or greater], rivaroxaban [last dose 10 mg or greater], edoxaban [last dose 30 mg or greater] or enoxaparin [≥ 1 mg/kg/d]):
- ≤ 15 hours prior to start of surgery.
- > 15 hours prior to start of surgery or unknown time from the last dose, if documented anti fXa activity is > 100 ng/mL (> 0.5 IU/mL for enoxaparin, or over the equivalent IU/mL threshold on a low molecular weight heparin assay; see Laboratory Manual) within 2 hours prior to consent. Note: Patients enrolled in this manner should receive a high-andexanet dosing regimen.
- Have a negative pregnancy test documented prior to enrollment (for women of childbearing potential).
- Willingness to use highly effective methods of contraception through 30 days following study drug dose (for female and male patients who are fertile).
Exclusion Criteria:
If a patient meets any of the following criteria, he or she is not eligible:
- Surgery for which the risk of clinically meaningful uncontrolled or unmanageable bleeding is low.
Acute life-threatening bleeding (ISTH criteria) at the time of Screening:
- The patient has acute-overt bleeding that is potentially life-threatening, e.g., with signs or symptoms of hemodynamic compromise, such as severe hypotension, poor skin perfusion, mental confusion, low urine output that cannot be otherwise explained.
- The patient has overt bleeding associated with a fall in hemoglobin level by ≥2g/dL, OR, a hemoglobin ≤8 g/dL if no baseline hemoglobin is available.
- The patient has acute bleeding in a critical area or organ, such as pericardial, intracranial, or intraspinal.
- Any surgical procedure that involves the intraoperative use of systemic, intravascular, unfractionated heparin.
- Primary procedure for efficacy assessment is a non-surgical interventional procedure (e.g, lumbar puncture, skin biopsy, cardiac catheterization, endoscopic retrograde cholangio-pancreatography).
- Expected survival of < 1 month due to comorbidity.
- Known "Do Not Resuscitate" order or similar advanced directive.
- The patient has a recent history (within 30 days prior to screening) of a diagnosed TE as follows: venous thromboembolism (including deep vein thrombosis, pulmonary embolism, intracardiac thrombus), myocardial infarction (including asymptomatic troponin elevations), disseminated intravascular coagulation, acute traumatic coagulopathy, cerebrovascular accident, transient ischemic attack, unstable angina pectoris hospitalization, or severe peripheral vascular disease.
- Acute decompensated heart failure or cardiogenic shock at the time of screening.
- The patient has sepsis or septic or severe hemorrhagic shock at the time of Screening.
- The patient has heparin-induced thrombocytopenia (with or without thrombosis).
- Inherited coagulopathy (e.g., anti-phospholipid antibody syndrome, protein C/S deficiency, Factor V Leiden) at time of Screening.
- Platelet count < 80,000/µL at the time of Screening.
- Last dose of apixaban < 2.5 mg, rivaroxaban < 10 mg, edoxaban < 30 mg, or enoxaparin 40 mg.
- The patient is pregnant or a lactating female.
The patient has received any of the following drugs or blood products within 7 days of enrollment:
- Vitamin K antagonists (e.g., warfarin).
- Dabigatran.
- Prothrombin complex concentrate products (e.g., Kcentra®) or recombinant factor VIIa (e.g., NovoSeven®).
- Whole blood, plasma fractions. Note: Administration of tranexamic acid, platelets or packed red blood cells is not an exclusion criterion.
- The patient was treated with an investigational drug < 30 days prior to Screening.
- Prior treatment with andexanet.
- Known hypersensitivity to any component of andexanet.
- Known allergic reaction to hamster proteins.
- Known or suspected (i.e., presumed positive) COVID-19-related illness at the time of Screening.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Achieving Effective Hemostasis
Time Frame: Hemostasis will be assessed from the start of surgery to the end of the procedure
|
Effective hemostasis is defined as excellent or good as assessed by the Investigator; Ineffective hemostasis is defined as moderate or poor as assessed by the Investigator.
All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.
|
Hemostasis will be assessed from the start of surgery to the end of the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline In Anti-fXa Activity To Treatment Nadir
Time Frame: Baseline, Treatment nadir (not to exceed a total of 6.5 hours of andexanet dosing)
|
Baseline is defined as the last non-missing value on or before first study drug administration.
On treatment nadir is the minimum value of anti-fXa activity during the period of time from the end of the andexanet bolus to the end of the andexanet infusion.
All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.
|
Baseline, Treatment nadir (not to exceed a total of 6.5 hours of andexanet dosing)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 27, 2021
Primary Completion (Actual)
November 23, 2021
Study Completion (Actual)
January 25, 2022
Study Registration Dates
First Submitted
January 14, 2020
First Submitted That Met QC Criteria
January 15, 2020
First Posted (Actual)
January 18, 2020
Study Record Updates
Last Update Posted (Actual)
March 22, 2023
Last Update Submitted That Met QC Criteria
February 24, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ALXN2070-19-515
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Surgery
-
3MRecruitingAbdominal Surgery | Orthopedic Surgery | Vascular Surgery | Cardiovascular SurgeryUnited States
-
Vanderbilt UniversityCompletedHand Surgery | Wrist Surgery | Forearm Surgery | Elbow SurgeryUnited States
-
Nantes University HospitalCompletedGynecological Surgery | Plastic Surgery | ENT SurgeryFrance
-
Edwards LifesciencesCompletedAbdominal Surgery | Pelvic Surgery | Non-Cardiac/ Non-Thoracic Surgery | Major Peripheral Vascular SurgeryUnited States
-
Maquet Cardiopulmonary GmbHNAMSARecruitingCardiac Surgery | Cardiopulmonary Bypass | Thoracic Surgery | Vascular SurgerySpain
-
Baylor Research InstituteChiesi USA, Inc.RecruitingSurgery | Cardiac Surgery | Surgery--Complications | Percutaneous Coronary InterventionUnited States
-
Vanderbilt UniversityEdwards LifesciencesCompletedCardiac Surgery | Thoracic Surgery | Heart Surgery | Heart Transplant
-
Cairo UniversityBatterjee Medical College; Taif UniversityCompletedSurgery | Bariatric SurgeryEgypt, Saudi Arabia
-
Surgify Medical OyCompletedSurgery | Spine SurgeryFinland
-
Poudre Valley Health SystemTerminatedSurgery | Surgery--ComplicationsUnited States
Clinical Trials on andexanet alfa
-
Alexion PharmaceuticalsPopulation Health Research Institute; Portola Pharmaceuticals, LLC (a wholly...CompletedBleedingUnited States, Belgium, Canada, France, Germany, Japan, Netherlands, Spain, United Kingdom
-
AstraZenecaLOGEX Healthcare Analytics Amsterdam The NetherlandsRecruiting
-
Alexion Pharmaceuticals, Inc.CompletedAcute Intracranial HemorrhageCanada, Denmark, Italy, Netherlands, Spain, United States, Belgium, Switzerland, Germany, Hungary, Russian Federation, Czechia, France, United Kingdom, Israel, Austria, Norway, Latvia, Finland, Poland, Sweden, Portugal, Greece, Lithuania
-
AstraZenecaOutcomes InsightsCompletedAnticoagulant-related Major BleedUnited States
-
AstraZenecaNot yet recruitingUrgent SurgeryFinland, Italy, Spain, United Kingdom, Belgium, United States, Switzerland, Germany, Hungary, Japan, Mexico, Austria, Australia, Israel, Czechia, Canada, Portugal, Bulgaria, China, Brazil, Taiwan, New Zealand, Slovakia, Poland, Estonia, G... and more
-
Portola PharmaceuticalsCompleted
-
Portola PharmaceuticalsTerminated
-
Portola PharmaceuticalsCompletedBleedingUnited States
-
Portola PharmaceuticalsCompleted
-
Portola PharmaceuticalsCompleted